This study investigates the prognostic value of dynamic changes in PCA3 mRNA levels found in the abdominal cavity drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of PCA3 mRNA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.
None
1. Received neoadjuvant endocrine/chemotherapy before surgery;
2. Urine leakage after surgery (positive creatinine test of drainage fluid).
The study will include male patients diagnosed with prostate cancer who need radical prostatectomy. Participants must have a preoperative diagnosis confirmed by biopsy and imaging studies. Eligible patients will have an abdominal drainage system in place post-surgery for fluid collection.
Cohort
Prospective
Not listed
PCA3 mRNA Levels in Drainage Fluid
PCA3 mRNA Levels in The Drainage Fluid Drained from The Abdominal Cavity
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
